10567381 - GAU: 1646

## SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

Substitute for form 1449/PTO

	Equivalent of Form F Toloblood (of co)			
Complete if Known				
Application Number	10/567,381			
371(c) Date	February 26, 2008			
First Named Inventor	Daniel H.S. LEE			
Art Unit	1647			
Examiner Name	WEGERT, Sandra L.			
Attorney Docket Number	2681.0430002/EJH/JBF			

U.S. PATENT DOCUMENTS					
Examiner initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Citied Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	US32	7,119,165 B2	10-10-2006	Strittmatter	
	US33	7,173,118 B2	02-06-2007	Strittmatter et al.	
	US34	7,456,255 B2	11-25-2008	Strittmatter et al.	
	US35	7,465,705 B2	12-16-2008	Lee et al.	
	US36	2008/0219984 A1	09-11-2008	Strittmatter	
	US37	2008/0274112 A1	11-06-2008	Lee et al.	
	US38	2009/0215691 A1	08-27-2009	Lee et al.	
	US39	2009/0175850 A1	07-09-2009	Strittmatter et al.	

FOREIGN PATENT DOCUMENTS						
Examiner		Foreign Patent Document	Publication	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
initials*	Cite No. <sup>1</sup>	Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY			T <sup>6</sup>
	FP21	WO 00/32221 A2	06-08-2000	Genentech, Inc.		
	FP22	WO 00/73452 A2	12-07-2000	Genentech, Inc.		

1116376 1.DOC

Examiner Signature	/Sandra Wegert/	Date Considered	11/04/2010
-----------------------	-----------------	--------------------	------------

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 8 Applicant is to place a check mark here if English language Translation is attached.

10567381 - GAU: 1646 Equivalent of Form PTO/SB/08b (7-09)

Substitute for form 1449/PTO				Сон	Complete if Known		
SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE			TAITAI	Application Number	10/567,381		
				371(c) Date	February 26, 2008		
				First Named Inventor	Daniel H.S. LEE		
STATEMENT BY APPLICANT (Use as many sheets as necessary)		Art Unit	1647				
		Examiner Name	WEGERT, Sandra L.				
Sheet	1	of	1	Attorney Docket Number	2681.0430002/EJH/JBF		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>		
	NPL44	Hunt, D., et al., "The Nogo receptor, its ligands and axonal regeneration in the spinal cord; A review," <i>J. Neurocytol. 31</i> : 93-120, Kluwer Academic Publishers, United States (2002)			
	NPL45	Pettit, D.K., and Gombotz, W.R., "The development of site-specific drug-delivery systems for protein and peptide biopharmaceuticals," <i>Trends Biotechnol.</i> 16: 343-349, Elsevier Science Publishers, England (1998)			
	NPL46	Copy of Office Action for United States Patent Application 11/055,163, Lee et al., mailed November 1, 2007			
	NPL47	NCBI Database, GenBank Accession No. AY028438, entry date March 22, 2001			

1116384\_1.DOC

Commission	Examiner Signature	/Sandra Wegert/	Date Considered	11/04/2010
	~		i i	8

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S.Apatent Bod Tatenay Trips (1988) (1998) (